Phase 1 trial of intrapleural LTI-01; single chain urokinase in complicated parapneumonic effusions or empyema

Lutz Beckert, … , Krishna Sarva, Steven Idell

JCI Insight. 2019. https://doi.org/10.1172/jci.insight.127470.

Background: Current dosing of intrapleural fibrinolytic therapy (IPFT) in adults with complicated parapneumonic effusion (CPE) / empyema is empiric, as dose-escalation trials have not previously been conducted. We hypothesized that LTI-01 (scuPA), which is relatively resistant to PA inhibitor-1 (PAI-1), would be well-tolerated.

Methods: This was an open-label, dose-escalation trial of LTI-01 IPFT at 50,000-800,000 IU daily for up to 3 days in adults with loculated CPE/empyema and failed pleural drainage. The primary objective was to evaluate safety and tolerability, and secondary objectives included assessments of processing and bioactivity of scuPA in blood and pleural fluid (PF), and early efficacy.

Results: LTI-01 was well tolerated with no bleeding, treatment-emergent adverse events or surgical referrals (n=14 subjects). uPA antigen increased in PFs at 3 hours after LTI-01 (p<0.01) but not in plasma. PF saturated active PAI-1, generated PAI-1-resistant bioactive complexes, increased PA and fibrinolytic activities and D-dimers. There was no systemic fibrinogenolysis, nor increments in plasma D-dimer. Decreased pleural opacities occurred in all but one subject. Both subjects receiving 800,000 IU required two doses to relieve pleural sepsis, with two other subjects similarly responding at lower doses.

Conclusion: LTI-01 IPFT was […]

Find the latest version:

http://jci.me/127470/pdf
Lutz Beckert\textsuperscript{1}, Ben Brockway\textsuperscript{2}, Graham Simpson\textsuperscript{3}, Anne Marie Southcott\textsuperscript{4}, Y.C. Gary Lee\textsuperscript{5}, Najib Rahman\textsuperscript{6}, Richard W. Light\textsuperscript{7}, Steven Shoemaker\textsuperscript{8}, John Gillies\textsuperscript{9}, Andrey A. Komissarov\textsuperscript{10}, Galina Florova\textsuperscript{10}, Timothy Ochran\textsuperscript{11}, William Bradley\textsuperscript{12}, Harrison Ndetan\textsuperscript{13}, Karan P. Singh\textsuperscript{13}, Krishna Sarva\textsuperscript{10} and Steven Idell\textsuperscript{10}

\textsuperscript{1}University of Otago, Christchurch, New Zealand; \textsuperscript{2}University of Otago Dunedin School of Medicine, Dunedin, New Zealand; \textsuperscript{3}Cairns Hospital, Cairns, Australia; \textsuperscript{4}Western Health, Footscray, Australia; \textsuperscript{5}Sir Charles Gairdner Hospital, Perth, Australia; \textsuperscript{6}Nuffield Department of Medicine, University of Oxford, Oxford, UK and Oxford NIHR Biomedical Research Centre; \textsuperscript{7}Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA; \textsuperscript{8}Nicosof LLC, Erie, Colorado, USA; \textsuperscript{9}Clinical Network Services (CNS), Auckland, New Zealand; \textsuperscript{10}Departments of Cellular and Molecular Biology, Innovation Initiative, Department of Radiation Oncology, Department of Epidemiology and Biostatistics, School of Community and Rural Health, The University of Texas Health Science Center at Tyler, Tyler, Texas, USA.

Correspondence:
Steven Idell M.D., Ph.D.
Professor of Medicine
The University of Texas Health Science Center at Tyler
11937 US HWY 271
Tyler, TX, 75708, U.S.A.
Email: steven.idell@uthct.edu
Telephone: 903-877-7556
FAX: 903-877-7316

\textbf{Conflict of Interest Statement}: NIH SMARTT HHSN268201100014C (SI) provided funding of the manufacturing of the drug substance, toxicology studies and regulatory support, NIH U01 HL121841-01A1(SI) provided initial funding in preparation for the clinical trial. Lung Therapeutics, Inc. (LTI) sponsored the trial. Dr. Idell serves as a Founder and Chief Scientific Officer of LTI and a member of the Board of Directors of LTI, which provided funding for preparation of the drug product and for the trial. He has an equity position (first tier COI) in the company, as does the University of Texas Horizon Fund and The University of Texas Health Science Center at Tyler (UTHSCT). He has a conflict of interest plan acknowledging and managing these declared conflicts of interest through The University of Texas Health Science Center at Tyler (UTHSCT) and UT System. He is an inventor on a patent USPTO # 7332469 held by the UT Board of Regents and licensed to LTI. Drs. Komissarov and Florova have received funding from LTI for this study and they and Mr. Sarva likewise have conflict of interest management plans at UTHSCT. Dr. Singh has an equity position in LTI. Drs. Komissarov, Florova and Idell are inventors on patent USPTO # 10,175,255 B2. Drs. Rahman and Lee serve as key opinion leaders for LTI and NR is paid for his input to...
the company. Dr. Shoemaker is a paid consultant for LTI and Dr. Gillies received payment as Medical Monitor for the study from LTI. Dr. Beckert has a potential conflict of interest having more than $50K funding support for personnel and laboratory work for this study from Lung Therapeutics, Inc. (LTI). Dr. Southcott received funding in the fiscal year prior to submission >$50,000 from GSK for 2 funded COPD trials. Dr Lee has led clinical trials for which Rocket Ltd provided pleural drainage kits for patients without charge. Dr Lee has served as advisor to LTI and CareFusion/BD.
Abstract

**Background:** Current dosing of intrapleural fibrinolytic therapy (IPFT) in adults with complicated parapneumonic effusion (CPE) / empyema is empiric, as dose-escalation trials have not previously been conducted. We hypothesized that LTI-01 (scuPA), which is relatively resistant to PA inhibitor-1 (PAI-1), would be well-tolerated.

**Methods:** This was an open-label, dose-escalation trial of LTI-01 IPFT at 50,000-800,000 IU daily for up to 3 days in adults with loculated CPE/empyema and failed pleural drainage. The primary objective was to evaluate safety and tolerability, and secondary objectives included assessments of processing and bioactivity of scuPA in blood and pleural fluid (PF), and early efficacy.

**Results:** LTI-01 was well tolerated with no bleeding, treatment-emergent adverse events or surgical referrals (n=14 subjects). uPA antigen increased in PFs at 3 hours after LTI-01 (p<0.01) but not in plasma. PF saturated active PAI-1, generated PAI-1-resistant bioactive complexes, increased PA and fibrinolytic activities and D-dimers. There was no systemic fibrinogenolysis, nor increments in plasma D-dimer. Decreased pleural opacities occurred in all but one subject. Both subjects receiving 800,000 IU required two doses to relieve pleural sepsis, with two other subjects similarly responding at lower doses.

**Conclusion:** LTI-01 IPFT was well-tolerated at these doses with no safety concerns. Bioactivity of LTI-01 IPFT was confirmed, limited to PFs where its processing simulated that previously reported in preclinical studies. Preliminary efficacy signals including reduction of pleural opacity were observed.

**Trial Registration:** ANZCT ID: ACTRN12616001442493.

**Funding:** Lung Therapeutics, Inc.(LTI), NIH SMARTT HHSN268201100014C(SI), UO-1 HL121841-01A1(SI). 1R01HL130402-01A1 (AK, GF, SI), UTHSCT AG18-09 (AK).

Wd Ct: 248.
Introduction

Complicated parapneumonic pleural effusions (CPE) or empyema with failed drainage and pleural sepsis are dire consequences of pleural infection and remain important clinical challenges. Serious pleural infections are reported to occur in about 90,000 patients annually in the US(1), are increasing in frequency in adults(2) and children(3) and are associated with a mortality rate of up to 20 percent(4). Patients often have hospital stays exceeding hospital Diagnosis Related Group (DRG)-payments to hospitals in the US and can require surgery to relieve pleural sepsis(5). Treatment entails costs of care of more than a third of a billion dollars in the US and UK (5, 6), indicative of a substantive global burden.

Intrapleural fibrinolytic therapy (IPFT) has been part of the therapeutic arsenal for CPE/empyema for over sixty years, predicated on the concept that lysis of the intrapleural, extravascular fibrinous neomatrix can pharmacologically relieve impaired drainage of purulent collections that support persistent pleural sepsis(7). While generally effective in children, the safety profile and efficacy of IPFT in adult patients currently remains unclear(8-10). A number of unapproved agents have been used to augment pleural drainage in adults with CPE/empyema, with variable results (11, 12).

We used single chain urokinase plasminogen activator; scuPA, as the interventional agent and tested its safety after intrapleural delivery as the primary study objective. LTI-01, a new form of scuPA produced in Chinese Hamster Ovary (CHO) cells, is an IPFT candidate which offers a number of conceptual advantages including relative resistance to inhibition by plasminogen activator inhibitor-1 (PAI-1), the major plasminogen activator (PA) inhibitor within pleural fluids (PFs) (13) and durable, low grade bioavailability in PFs over 24h(13). Extensive analyses including Good Laboratory Practice (GLP)-toxicology studies performed as part of NHLBI SMARTT (Science Moving Towards Translation and Therapy) contract # HHSN268201100014C demonstrated that this was a well-tolerated agent, including after intrapleural administration. In extensive preclinical testing, scuPA IPFT effectively cleared fibrinous collections associated with several forms of pleural injury including empyema(13-18).

A major impediment to interpretation of all trials concerning the efficacy and safety of IPFT to date has been that the dosing of IPFT has been empiric, with dosing of all forms of IPFT subject to arbitrary rather than evidence-based selection(19, 20). We are unaware of any previous phase 1; dose-escalation, trials done to establish dosing and safety as a prelude to efficacy testing in the IPFT field. Further, we are unaware of any prior reports in which PF bioactivity or processing of any of the IPFT agents was examined.
Such analyses were not included in the design of the large and influential MIST1 and 2 phase 2 studies\(^4,\)\(^5\). In the present report, we sought to address these critical gaps in two ways. First, we conducted the first in-field dose-escalation trial of any intrapleural fibrinolysin and tested intrapleural recombinant LTI-01 in patients with pre-hoc CPE/empyema, pleural loculation and failure to drain. Second, we integrated first-in-kind comprehensive analyses of the intrapleural and systemic processing of LTI-01 into the protocol design. These analyses enabled us to assess the safety and PF bioactivity of dose-escalated LTI-01 IPFT in adult CPR/empyema subjects and to better understand its contribution to treatment outcomes better.

**Results**

**Demographics.** The Intent To Treat (ITT) population comprised all subjects (n=14) who enrolled in the study and supplied post-screening data. The ITT population was used for summaries of all disposition, demographic and other baseline data. The demographics of the ITT population are illustrated in Table 1. All 14 subjects received antibiotics prior to and at screening. After study entry, they were continued on the regimens listed in Supplement Table 1, which also describes the pleural fluid characteristics, biomarkers and cultures. PF cultures were positive for 4/14 patients at study entry, one was not cultured, and 9 yielded no growth. Three of the four PF positive cultures yielded *Streptococcal* species. Blood cultures were negative in all patients. All subjects had purulent PF, Gram stain or culture positive or pH ≤7.2, and had loculated PF by chest imaging with failure to drain over 3h of initial observation (Figure 1).

**Safety Results**

**Bleeding Events.** No acute intrapleural or systemic bleeding events were observed in any of the LTI-01-treated subjects. There were likewise no consistent effects on heart rate, blood pressure, respiratory rate or temperature at all dose levels. Fever (>37.4°C) was present in only 1 patient.

**Treatment-emergent adverse events (TEAEs).** Assessments were done according to the study schedule (Supplement, Table 2 and Study Protocol). A total of 22 TEAEs were recorded in 7 (50.0%) of the 14 subjects (Table 2). No TEAE was considered to be related to study treatment, based on treating physician assessment. TEAEs did not increase with dose level, as 10 were recorded in the low dose group (50,000 IU), compared to no such events in the high dose group (800,000 IU). The most frequently occurring TEAEs were hypotension and post-procedural persistent drain fluid (3 events each), and pleuritic
pain (2 subjects each). Three TEAEs occurring during active study participation were classified as severe including metastatic squamous cell carcinoma, sinus tachycardia, lung abscess, and 11 were classified as moderate. There were two further TEAEs of note, neither attributed to LTI-01. One subject (200,000 IU) had a post-procedural hematoma pre-dose on Day 3. That was considered unlikely to be related to study drug by the local investigator and thought to be related to drain insertion. The other (50,000 IU) had sinus tachycardia. There were no life-threatening TEAEs and none led to study discontinuation.

**SAEs.** Serious Adverse Events (SAEs) were collected from the time of first study dose to Day 28, hospital discharge or death, whichever came first (Supplement, Table 3). Two subjects experienced SAEs, both leading to death, with neither death attributed to administration of LTI-01. One subject (50,000 IU) with clinical empyema and failure to drain at enrollment died from metastatic squamous cell carcinoma on Day 20. This subject had the condition in addition to CPE, given that malignant cells were found in his PF after entry. A second subject (400,000 IU) has a ruptured lung abscess and died of a contralateral pneumonia on Day 86. This subject had a cavitating lung lesion of the right lower lobe, pneumonia, empyema and obstruction of his bronchus intermedius as well as bile duct obstruction at entry. No additional SAEs occurred after Day 28 or after discharge as of database lock (10 May, 2018). No protocol deviations were considered to affect study objectives or the integrity of the data (Supplement, Section 1).

**Treatment compliance.** Six of the 14 subjects did not receive dosing on Day 3. In accord with the protocol, second or third LTI-01 doses could be withheld if complete resolution of the pleural process occurred after the prior dose. In one patient in the 50,000 IU group, treatment was stopped after two doses of LTI-01 after which tPA, or tPA/DNase was administered on days 3-5 by the treatment team. In a subject in the 100,000 IU group, LTI-01 was not given on day 3 because of an elevated PT of 16 sec. This subject received tPA/DNase on days 5-8 because of an increased leukocyte count and increased CRP. Another patient in this group did not receive the third dose of LTI-01 because of chest tube migration and required no further therapy. The subject in the 200,000 IU group with a chest wall hematoma did not receive the third dose because of clinical improvement following LTI-01 IPFT. In a patient in the 800,000 IU group it was felt that a third dose was likewise not warranted because of radiographic/clinical improvement. In the other subject in this group, a partial third dose was given because of chest tube blockage and the patient required no further IPFT.

**Clinical laboratory testing.** Mean hemoglobin decreased at all time points for the pooled subject population, while total leukocyte and neutrophil counts generally decreased during and after LTI-01 IPFT (Supplement Figures S1-3. There was no consistent effect or effect over time of LTI-01 IPFT on mean PT,
mean activated partial thromboplastin time (aPTT) or mean international normalized ratio (INR) values. Plasma fibrinogen never fell below the top normal lab range levels in any subject, indicating no evidence of systemic fibrinogenolysis (Supplement, Figure S4). There were no changes in blood chemistries attributable to LTI-01 IPFT (not shown).

**Preliminary Assessments of Efficacy.** No subject was referred to surgery. None experienced a life-threatening event prior to discharge. All but one subject with underlying pleural malignancy identified after entry had a relative decrease in pleural density area or volume during the study (Table 3). Total PF drainage volumes were measured daily and exhibited increased volumes that tended to increase with dose. Total PF drainage volumes from day 1 to 23 hours after the final dose or at day 4, whichever came first, were 248.7, 525.3, 651.7, 1299.8 and 1585.0 mL for the LTI-01 50,000, 100,000, 200,000, 400,000 and 800,000 IU dose levels, respectively. Mean plasma CRP decreased at all time points for the pooled subject population. A maximum decrease from baseline concentrations was found by Days 7 to 28 at -125.4 mg/L, with a rate of decrease trending lower during the treatment phase (Supplement, Figure S5).

**Follow up at 3 and 12 Months after LTI-01 IPFT.** Data was available at 3 mo. for all 12 patients known to survive beyond 86 days. At 3 mo., no additional deaths occurred, nor were there any further hospitalizations for pleural disease, including surgery. Information was available for 10/12 subjects at 12 months, with no referrals to surgery or hospitalizations.

**Pharmacokinetic (PK), pharmacodynamic (PD) analyses, and intrapleural processing of LTI-01.** uPA-related antigen (labeled as urokinase) data are provided in the Supplement, Table 4. PF uPA antigen levels (Figure 2A; PD) at 3 h after delivery were markedly elevated, when compared to pre-injection levels (p<0.05). They ranged from a mean Day 1 postdose (3 hour) level of 376,830 pg/mL in the 50,000 IU dose group compared to 2,129,776 pg/mL in the 800,000 IU dose group (Figure 2A). The level of the uPA antigen at 23 h (Day 2 pre-dose) was also higher (p<0.05) than that before treatment (Day 1 pre-dose). There was no statistically significant difference (p>0.05) between PF uPA antigen levels on day 1, 2 or 3 at 3 h after treatment. These results reflect successful delivery of the LTI-01 to the pleural space, maximal detectable levels at 3 h and retention of the elevated uPA antigen up to 23 h. Plasminogen activating (PA) and fibrinolytic activities were next determined in all PF samples. As expected, changes in the PF PA activity with time (Figure 2B) paralleled those observed for uPA antigen (Figure 2A). While PA activity was relatively high at 3 h post treatment, it was at or below the limit of detection at baseline and at 23 h after IPFT (Figure 2B). Notably, PF fibrinolytic activity was also relatively high at 3 h after IPFT and suppressed at the baseline and 23 h (Figure 2C). PF levels of fibrin degradation products (D-dimers) (Figure 2D)
increased at 3 h post treatment and temporally correlated with changes in fibrinolytic activity. These results confirm bioavailability of LTI-01 in PFs of treated patients with conversion into mature two-chain enzyme, activation of endogenous plasminogen (Supplement Figure S6), and generation of durable fibrinolytic activity, with an increase in PF D-Dimers; the products of fibrinolysis in PFs. Plasminogen levels were unchanged in plasma.

**Effects of LTI-01 on changes of the fibrinolytic system in plasma.** In contrast to PF (Figure 2A), plasma uPA-related antigen levels (PK) did not significantly increase after dosing on Day 1 at 3-hour post-dose compared with pre-dose (Figure 2E) or at other dosing intervals. The largest increase was seen in one of the subjects dosed at 800,000 IU with an increase of approximately 700 pg/mL post-dose (1446 pg/mL) compared to the pre-dose level (743 pg/mL). Notably, uPA antigen levels in plasma (Figure 2E) were almost three orders of magnitude lower than those in PF at 3 h post-treatment (Figure 2A). Moreover, while the level of uPA antigen in the PF changed with time, uPA in the circulation remained stable (Figure 2E). Similar to uPA, the levels of D-dimers in plasma (Figure 2F) were up to three orders of magnitude lower than those in PF (Figure 2D). Plasma D-dimers did not change (p>0.05) during the 3-day treatment period (Figure 2F), indicating no significant systemic changes in fibrinolytic activity.

**Endogenous inhibitors affect LTI-01 and intrapleural fibrinolysis.** Intrapleural concentrations of active PAI-1 in all pre-treatment samples were elevated (160-200 ng/ml; Figure 3A) resulting in the observed inhibition of the plasminogen activation (Figure 2B) and fibrinolysis (Figure 2C). On the other hand, the level of active PAI-1 in the majority of PF samples collected at 3 h post treatment with LTI-01 was at or below the limit of detection (Figure 3A; p<0.01 versus baseline levels). Thus, PAI-1 activity at 3 h was completely inhibited by PF LTI-01, which promotes its conversion to two-chain uPA to activate endogenous plasminogen and thus support intrapleural fibrinolysis. Interestingly, four samples with elevated PAI-1 activity detected at 3 h (one at Days 1 and 3 and two at Day 2; Figure 3A; post) possessed no PA activity. Thus, an increase in the active PAI-1 at 3 h likely indicates either incomplete delivery of IPFT or fast *in vivo* inactivation of LTI-01 in PFs of these particular patients. PAI-1 total antigen was also significantly increased in PFs (Figure 3B) versus levels found in the plasma (not shown), reflecting overexpression of local PAI-1 in infectious pleural injury. The increase in the PF levels of uPA antigen at 23 h, when compared to the baseline (Figure 2A) without a significant increase in PA activity (Figure 2B) is consistent with formation of bioactive complexes with alpha2--macroglobulin (A2M), as observed in pre-clinical models of pleural injury(13). Indeed, levels of intrapleural A2M/uPA complexes (Figure 3C) increased at 3 h after IPFT and decreased at 23 h post-treatment. Next, we tested the concept of
Fibrinolytic Potential (FP) as a personalized predictor of the response to LTI-01 IPFT (21, 22). Supplementation of the pre-dose (baseline and at 23h) PFs with two chain uPA (the FP) generated robust levels of fibrinolytic activity (median 0.7-1.3 AU; p<0.01 versus unsupplemented baseline levels). We evaluated PF samples collected prior to treatment and correlated the FP to changes in the pleural density area, as assessed by CXR. There was a significant correlation between the FP (Figure 3D; n=8; r= -0.79, p<0.05) with the % relative change of CXR pleural density area post-treatment (Table 3 and panel A).

Individualized assessments of derangements of PF components of the fibrinolytic system and outcomes of LTI-01 IPFT. First, we analyzed the findings in subjects with clinical improvement proximate to LTI-01 administration without any switch to another form of IPFT or referral to surgery and reduced pleural opacification by either CXR or chest CT imaging. One patient in the 400,000IU group; 102-1005, received all three doses and temporally responded with clinical resolution of pleural sepsis and a relative reduction of pleural density of 45%. Interestingly, this patient demonstrated the highest levels of uPA antigen; >100 µg/ml, in post-treatment pleural fluids as well as the lowest levels of PAI-1 PF concentrations. In another patient in the 800,000IU group; 102-1007, clinical resolution of pleural sepsis was achieved with a relative reduction in the pleural density of 36%, so that a third dose of LTI-01 was not administered. This patient had elevated levels of PF uPA >100 µg/ml with low levels of PF PAI-1 compared to other subjects (Supplement, Figure 7A, B). In the other patient receiving 800,000 IU, only a portion of the third dose was delivered attributable to chest tube obstruction and pleural sepsis likewise resolved without further IPFT or a referral to surgery and PF PAI-1 levels remained low at days 1 and 2 post-dosing. One additional patient; 102-1001, treated with 50,000 IU/ml drained effectively with a relative reduction of pleural density of 85% by chest X-ray, had relatively very low levels of PF PAI-1 with concurrent increments of uPA and resolution of clinical pleural sepsis upon completion of LTI-01 dosing (Supplement, Figure 7A and B). Other patients with poor outcomes remote to the treatment period had relatively elevated levels of PAI-1 or did not complete therapy while those that responded clinically and radiographically typically had evidence of appropriate drug delivery with elevated PF uPA and reduced PAI-1 activity, as described in detail for all other subjects (n=10) in the Supplement, Section 2 and Figure S7.

Discussion

Since the inception of IPFT (7, 23), a number of fibrinolysins, which activate plasminogen to form plasmin and lyse fibrin, have been used to treat adults with CPE/empyema (19, 24). In previous meta-
analyses, it was concluded that there was equivocal evidence supporting the use of IPFT for these patients\(^{(8, 9)}\), with a more recent study unable to assess the impact of IPFT\(^{(10)}\). Among factors contributing to the uncertainty, IPFT dosing remains empiric and bioactivity of currently used IPFT agents was not confirmed in prior clinical trial testing in adults with empyema/CPE \(^{(19, 20, 25)}\).

In addition, to our knowledge, no form of IPFT has been approved by any regulatory agency in the US, UK or elsewhere to date. A major initial requirement for such approval is the performance of phase 1 testing in humans to establish safety. We manufactured a highly purified recombinant active pharmaceutical form of scuPA to meet requirements for regulatory approval. Initial dosing for this trial was established with GLP toxicologic studies. The drug product; LTI-01, was used in what we believe to be the first dose-escalation safety trial with CPE/empyema.

The premise for testing LTI-01 is based upon its favorable biochemical properties and unique processing in PFs. Over the past twenty years, our group published several preclinical studies suggesting that scuPA was effective and well-tolerated in organizing pleural injury, as reviewed recently\(^{(20)}\). First, scuPA was found to be well-tolerated and in tetracycline-induced pleural injury and empyema in rabbits and cleared pleural collections without causing intrapleural or systemic bleeding\(^{(13-16)}\). Secondly, scuPA IPFT is relatively PAI-1 resistant in PFs\(^{(13)}\). This issue is of particular importance, given the characteristically high levels of PAI-1 that occur within empyema/CPE PFs \(^{(15, 26, 27)}\) and as confirmed in this study. While other inhibitors, including antiplasmins are present in CPE/empyema PFs, increased pleural organization associated with PAI-1 overexpression\(^{(17)}\) attests to its impact on outcomes. We found that levels of total and active PF PAI-1 are variably increased in patients with CPE/empyema, which implies that current empiric selection of IPFT could predispose to bleeding in some patients with relatively low PF PAI-1 or be insufficient in those with high PAI-1. This variability also may explain why LTI-01 IPFT was effective over a range of doses in individual subjects with different levels of PF PAI-1.

The demographic profile of the subjects reflects the variety of causes of pleural infection that may lead to loculation and failed pleural drainage. Subjects had a mean age of about 65 years, comparable to the cohorts previously enrolled in the MIST1 and 2 trials\(^{(4, 5)}\). A limitation of the study is that only 14 of the 21 subjects that could have been enrolled actually participated and there was no expansion of any of the cohorts as allowed by the protocol design (Supplement, Study Protocol).

Two consecutive patients who received the highest dose of 800,000 IU tolerated the drug well and required only two doses to relieve the pleural collection. Two (2) subjects died during the follow-up
period after active study participation. Neither death was attributed to LTI-01 by the local investigator. The maximal tolerated dose (MTD) of LTI-01 IPFT was not detected. However, the absence of safety signals offers a strong rationale for further dose escalations to identify the optimal dose to be tested in the next phase of development. Higher dose escalations were not included in the study design because of limited drug supply.

There were no bleeding events, either local or systemic in the study participants. This observation is of particular importance given reported bleeding rates of 5-28% associated with different forms of IPFT (28, 29), despite some reports of lesser incidences (12, 30). The absence of clinical bleeding was in keeping with our preclinical experience (11, 13, 14, 16, 18, 21, 31, 32) and pre-trial toxicology. The initial dose of 50,000 IU was felt to likely be subtherapeutic based on the literature (11, 33). However, it was intentionally used to determine how well the study drug/vehicle/known impurities (Supplement, Protocol) were tolerated before escalating the dose. The exclusion criteria we used also had rigorous provisions designed to decrease bleeding risk associated with this trial (Supplement, Protocol). These included abnormalities of the screening coagulation profile, known platelet dysfunction or use of anti-platelet agents. Patients could receive deep vein thrombosis prophylaxis but not full anticoagulation, given reports of increased bleeding risk (34, 35). Patients with a glomerular filtration rate of < 30 were also excluded. Plasma fibrinogen levels were screened, as levels below 100-150 mg/dL have been linked to bleeding risk in trauma patients (36-38).

All patients maintained supraphysiologic levels of plasma fibrinogen, which is an acute phase reactant and plasma levels remained elevated throughout the treatment period. The data indicate that administration of LTI-01 IPFT was not associated with fibrinogenolysis and suggest that future screening for fibrinogen levels does not need to be routine in the adult CPE/empyema population. There was no consistent effect of LTI-01 IPFT on the coagulation profiles of treated subjects.

Reduced pleural opacification was generally observed by chest X-ray or chest CT imaging, using the methodology originally reported in the MIST2 trial (5). As a safety trial, this study was not powered to delineate efficacy. Therefore, this readout needs to be considered as encouraging but preliminary. PF drainage increased after LTI-01 IPFT but occurs with other forms of IPFT such as tPA/ DNase IPFT (5). All baseline assessments approximated the screening or Day 1 pre-dose period and post-treatment assessments approximated the day 4 post treatment interval, but some were obtained at later intervals, representing another confounder (Supplement). Nonetheless, LTI-01 IPFT was temporally associated with improved pleural opacification and concurrently improved the clinical status in four patients, including
both subjects treated with 800,000 IU. These findings that support advancement to additional dose
escalations/group expansion. Decreases in plasma CRP levels and in white cell and neutrophil counts that
generally occurred in the subjects are consistent with improvement of the underlying pleural infections.
Lastly, the 4 subjects who received follow-up IPFT with tPA+/−DNase were all treated at one site and at
the discretion of the treating team, which was permitted under the protocol.

To our knowledge, this is also the first study to assess the bioavailability and processing of IPFT in
humans. PF analyses of uPA antigen (Figure 2A), PA and fibrinolytic activities (Figure 2B and C), D-dimers
(Figure 2D) indicate that successful delivery of LTI-01 resulted in activation of the endogenous
plasminogen and retention of elevated intrapleural PA and fibrinolytic activities up to 3 h after the
treatment. No systemic activation of fibrinolysis was detected (Figure 2E, F). Notably, both PF PA and
fibrinolytic activities were inhibited by 23 h after LTI-01 IPFT, supporting the use of daily dosing. Inhibition
of the fibrinolysis at 23 h was accompanied by an increase in the level of intrapleural active PAI-1 (Figure
3A), which inhibits PA activity (Figure 2B), and local generation of plasmin. Notably, the inhibition of the
fibrinolysis at 23 h was independent of the dose of the LTI-01 or the day of the treatment. Moreover, the
levels PF plasminogen and active PAI-1 observed at 23 h after the treatment were similar to those
detected at the baseline (Figure 3A). Thus, at all pre-dosing intervals, plasminogen was sufficient to
support plasmin generation by LTI-01 IPFT in PFs and confirmed by PF plasminogen levels (Supplement).
The correlation of the FP, a new companion diagnostic, with changes in opacification (Figure 3D) provides
preliminary support for its application as a predictor of IPFT efficacy and justifies future testing of its ability
to predict IPFT outcomes. The levels of PAI-1 antigen achieved in the PFs of patients in this study were
comparable to those previously reported.(26, 39, 40). Consistent with our more recent report(18), PAI-1
activity was also markedly increased in these PFs. Increased levels of PF bioactive uPA-α2macroglobulin
complexes at 3h after LTI-01 IPFT were generally identified (Figure 3C) and suggest that the mechanism
of processing and bioavailability of LTI-01 IPFT used in these subjects was comparable to that of scuPA
IPFT (Abbott Laboratories, glycosylated scuPA derived from S2 cells) used in our models of pleural injury
and empyema(13, 18).

The biochemical analyses we conducted allowed us to assess how individual responses to LTI-01
IPFT impacted outcomes These analyses helped us explain the efficacy of lower dosing of LTI-01 in some
patients. The favorable results in the 800,000 IU-treated group are especially encouraging. We ultimately
plan to advance this dose and conduct further dose escalations as a part of phase 2 testing. Ultimately,
we hope to identify a dose of LTI-01 that is well-tolerated by patients with CPE/empyema and that can be effective in almost all patients, including those with high levels of PF PAI-1 activity.

In summary, this study offers several contributions that are novel to the field. LTI-01 was safe at the doses we tested. It was bioactive in CPE/empyema PFs. Analyses of the FP and processing of LTI-01 and perhaps other IPFT agents can inform understanding of treatment outcomes in individual subjects. Treatment benefits observed in some subjects support the advancement of LTI-01 to further clinical trial testing.

**Methods**

**Involved centers and Ethics Approvals.** The trial included a total of 7 sites, of which 3 sites were in New Zealand, including Auckland City Hospital, Auckland; The University of Otago-Christchurch Hospital, Christchurch and Dunedin Hospital, Dunedin. There were 4 sites in Australia, including Westmead Hospital, Westmead, Sydney; Cairns Hospital, Cairns; Footscray Hospital/Western Health, Footscray, Melbourne and Sir Charles Gairdner Hospital, Nedlands, Perth.

**Trial objectives.** The primary objective was to evaluate the safety and tolerability of escalating doses of intrapleural LTI-01. Secondary objectives were to evaluate pharmacokinetic (PK) and pharmacodynamic (PD) effects of escalating doses of intrapleural LTI-01 and to assess efficacy parameters in subjects treated with escalating doses of intrapleural LTI-01. The intrapleural and systemic processing of LTI-01 was also evaluated by assessments done in PF and plasma obtained from each subject.

**Subjects.** Subjects with a clinical presentation compatible with pneumonia and a parapneumonic effusion, who had PF requiring drainage and whose pleural space failed to drain within 3 hours of tube thoracostomy and who were ≥21 years of age. Safety precautions included exclusion of cognitively impaired and institutionalized persons, exclusion of subjects with other disease processes that may have interfered with the interpretation of results (See Supplement, protocol). All subjects underwent tube thoracostomy and attempted drainage of their infected PF prior to study enrollment and were to be recruited only if their pleural space could not be drained within 3 hours after tube thoracostomy. Subjects were to receive all other customary therapy for CPE/empyema, including antibiotic therapy. The first subject was enrolled was March 7, 2017 and the date the last subject was completed was March 26, 2018.
Identity of Investigational Product. LTI-01 was supplied as a sterile, single-use vial containing approximately 60,000 IU (0.5 mg) of scuPA in a formulation of 5 mM citrate, 25 mM sodium chloride and 15 mg/mL mannitol, pH 4.5. LTI-01 is a lyophilized drug product reconstituted with 1.0 mL of water for injection. The drug substance was manufactured through NHLBI SMARTT, with lyophilization and vialing completed with support provided by Lung Therapeutics, Inc. The reconstituted material was administered via chest tube followed by a ‘chase’ to bring the total injected volume (LTI-01 plus saline chase) to 30 mL.

Method of Assigning Subjects to Dose Levels. Subjects were assigned sequentially to dose level. Blinding was not done, as this was an open label study.

Selection of Doses in the Study. Dosing was first based on studies in models of intrapleural injury that demonstrated therapeutic benefit and tolerance and bioavailability of LTI-01 (13, 15, 16, 41). We sought to initiate dosing at a level that was likely to be at or near a potentially therapeutic dose, since the study subjects had potentially life-threatening conditions. To balance this intention with a safe starting dose, a maximum recommended starting dose (MRSD) was calculated based on an assumption of an intrapleural no observed adverse effect level (NOAEL) of 0.25 mg/kg based on toxicology in rabbits and dogs, converting that dose to the human equivalent dose by allometrically scaling the dose based on body surface area and then adding a 10-fold safety factor to account for interspecies variation. This calculation resulted in an acceptable maximal safe starting dose of ~130,000 IU of LTI-01 for a 60 kg subject. To be conservative, we opted to initiate at a lower dose to assess potential effects of vehicle and impurities.

Trial Methodology: This was a prospective, open-label, dose escalation safety trial. Eligible subjects began treatment with intrapleural LTI-01 within approximately 24 hours of initial consent and enrollment. Treatment was administered as a bolus dose through the chest tube into the pleural space and allowed to stay in the space for 3 hours. Treatment was given once per day for up to 3 days. A dose escalation design was used, with up to 5 dose escalation cohorts as shown in Supplement, Protocol. Following the review of safety data from Cohort A (50,000 IU LTI-01) subjects by a Safety Review Committee (SRC), the dose level was escalated (doubled) in each consecutive group of 3 subjects with dosing for up to 3 days at all dose levels. A total of 21 patients could have been enrolled.

The study protocol permitted completion of dosing after < 3 daily doses with complete resolution of the pleural process. Bleeding events were defined as an acute bleeding event with ≥2 g/dL drop in blood hemoglobin; development of melena, hemothorax or PF/blood hematocrit >50%.
All subjects at all dose levels were observed for 4 days after last intrapleural LTI-01 treatment (or until hospital discharge if sooner). Clinical stability was to be documented before treatment of the next subject. Blood and PF assessments included complete blood counts (CBC)s, coagulation and metabolic profiles, fibrinogen and CRP levels done before and at 3 and 23 h after dosing. Chest X-ray and CT scans and other safety assessments were also performed before and on about 4 days after administration of LTI-01.

Blood and PF cultures were obtained, as well as other diagnostic tests deemed appropriate, including atypical pneumonia serology and pneumococcal antigen at screening. Procedures included chest X-ray and CT imaging and measurement of chest tube drainage, chest tube flushes and drain suction. Use of alternative forms of IPFT or referral for surgery was to occur as needed after completion of administration of LTI-01 unless circumstances necessitated earlier institution.

A displaced thoracostomy tube was only to be replaced if clinically indicated for PF drainage and not solely for trial drug administration. If the chest tube displacement occurred over a period of less than 48 hours, the trial treatment course could be restarted and completed, after chest tube replacement, if clinically indicated to complete the planned LTI-01 IPFT. Study drug administration was to be delayed if the prothrombin time/partial thromboplastin time (PT/PTT) was >1.7 x control or PT >15 seconds, or fibrinogen was <150 mg/dL, at the last available time point prior to dose administration (typically within 3 hours prior to dose administration). To mitigate against these changes, prophylaxis for deep vein thrombosis (DVT) was delivered as far removed as possible (e.g. 9-12 hours) from IPFT. Continued dosing was only allowed if the PT/PTT was ≤1.7 and PT <15 seconds and fibrinogen was >150 mg/dL. In otherwise stable subjects, transfusion for downward drift of blood hemoglobin that may have reflected marrow suppression as a result of acute illness, hemodilution or IPFT was not considered as a stopping criterion.

**Safety Assessments including Adverse Events.** Dr. Idell served on the Safety Review Committee with Dr. Gillies, Dr. Simpson, Dr. John Wheatley, Westmead Hospital, Sydney, AU and Dr. John Kolbe, Auckland City Hospital, NZ. Subjects were monitored for all Treatment Emergent Adverse Events (TEAEs) starting prior to the first study dose (Day 1 at the time of initiation of administration of Dose 1) until 23 hours after last dose of LTI-01. At each contact with the subject, information regarding AEs was elicited by appropriate questioning and examinations. Grade 3 and Grade 4 AEs were collected from the time of first study dose through to Day 7 or hospital discharge, whichever came first. SAEs were collected from the time of first study dose through to Day 28, hospital discharge or death, whichever occurred first. AEs overall are listed in the Supplement, Table 3.
**Efficacy endpoints of the study.** Vital signs were monitored and referrals for surgery and mortality during hospitalization, radiographic improvement based on comparison of pre-treatment chest X-ray or CT scan to those done 23 ± 3 hours after the last received daily dose of LTI-01 IPFT, as previously reported(5). The first radiographic study was an upright 2-view chest X-ray. Pleural effusion was confirmed radiographically. If pleural loculation was suggested on the plain chest X-ray, it was confirmed using CT scanning of the chest or chest ultrasonography. CT scanning (high resolution if available) was done unless precluded by the clinical status of the subject or unavailability of the test. At 23 ± 3 hours after the third (or final) dose of LTI-01, PF related density was compared by follow-up chest X-ray, with relative change in pleural opacification versus baseline imaging, as previously described (5). Days of hospitalization for this episode of CPE/empyema, total PF drainage from an initial dose of LTI-01 IPFT until 23 hours after the last LTI-01 IPFT dose versus baseline, stability or decline of white and neutrophil cell counts in blood and C-reactive protein (CRP) levels in plasma were also assessed. The volume of drainage from the chest tube was documented daily for up to 23 h after last dose and totaled for the full course (up to 3 days) of treatment.

**Central Laboratory Analyses.** These studies were done at UTHSCT and included D-dimer and PA as well as fibrinolytic activity levels in plasma and pleural fluids. Levels of PAI-1 antigen and activity levels were also assessed(18) as were levels of bioactive alpha 2-macroglobulin/uPA complexes(13). The fibrinolytic potential (FP); measurement of fibrinolytic activity after supplementation of baseline PFs with two-chain uPA was determined in samples of PF collected prior to the IPFT as previously described(21, 22). A total of n=8 PFs were available for these analyses.

**Pharmacokinetics (PK) and pharmacodynamics (PD) analyses.** These included total uPA antigen PK and PD in plasma and pleural fluids. A uPA ELISA; Quantikine ELISA (Urokinase, R&D Systems, DUK00, Lot # 171962), was used to perform these studies. The assay measures uPA-related antigen and detects single-chain uPA, two-chain uPA, uPA-PAI-1 complexes, and uPA bound to its receptor (uPA-uPAR complexes). Samples of PF and plasma were collected at the intervals stipulated, using methods appropriate for these assessments (Supplement, Table 4).

**Prior and Concomitant Therapy.** Subjects were expected to receive customary care including radiologic chest tube placement and initiation of antibiotics prior to enrollment. Radiologic tube placement, while not required, was considered justified as large bore tubes had not been proven to be more effective, were associated with greater morbidity, and radiologically placed tubes had the advantage of being located
within the PF collection. Subjects could receive all other customary therapy for CPE/empyema. Antibiotic regimens used were at the discretion of the managing physician.

**Subject Follow-up.** At 3 and 12 months after treatment, attempts were made to document surgical referral, further hospitalization for CPE/empyema and mortality in treated subjects through the outpatient clinic.

**Statistics.** All statistical analyses were exploratory in nature with descriptive statistics (i.e. mean, standard deviation, median, maximum and minimum) provided for continuous variables. Categorical variables are summarized by frequency distributions (number and percentage of subjects). The intent-to-treat (ITT) population comprised all subjects who enrolled in the study and who provided any post-Screening data. Pairwise comparisons depicted in Figures 2 and 3 were done using the Wilcoxon matched-pairs signed rank test. Because we assume that the pleural fluid and plasma environments differed each day as a result of different durations of antibiotics and other treatments, pairwise comparison of separate samples was done. As such no correction for multiple comparisons was warranted. Correlations were assessed using Spearman rank correlation analysis (depicted in Figure 3). Statistical significance for each test was assessed at the 5% level of significance.

**Study Approval and Registration.** Written informed consent was received from all participants prior to inclusion in the study. Ethics approvals were obtained from all required organizations, including: 1) The Western Sydney Local Health District Human Research Ethics Committee, Westmead Hospital, Westmead NSW 2145, Australia 2) Sir Charles Gairdner and Osborne Park Health Care Group Human Research Ethics Committee Nedlands WA 6009, Australia and 3) Northern B Health and Disability Ethics Committee Health and Disability Ethics Committees, Ministry of Health Wellington 6011, New Zealand. This trial complied with the ethical principles of Good Clinical Practice (GCP) and International Council on Harmonization (ICH) guideline, and with the Declaration of Helsinki. Subjects had the right to refuse participation without explanation and could withdraw at any time without affecting their follow-up care. In addition, clinicians managing the subject could choose alternative treatment at any time in the best interest of the given subject. Medical confidentiality was preserved, and personal identifying information was not revealed.

**Author Contributions.** LB, BB, GS, AMS, YCGL served as site Principal Investigators and recruited/managed patients enrolled in this study. SI, YGCL, RWL and NR helped to design and review the protocol. JG and SI served of the Safety Review Committee along with representatives of the Australian and New Zealand sites. JG served as Medical Monitor. SS, SI reviewed and organized the data, including that from the Clinical
KS, HN and GF performed statistical analyses. AAK, GF coordinated and with KS performed the sample biochemical analyses. AAK and GF analyzed, plotted and interpreted this data. TO and WB independently performed and with SS prepared the imaging analyses. SI, SS, AAK, GF and NR prepared the manuscript, which was reviewed by all authors.

Reference List
1. Grijalva CG, Zhu Y, Nuorti JP, and Griffin MR. Emergence of parapneumonic empyema in the USA. *Thorax*. 2011;66(8):663-8.
2. Farjah F, Symons RG, Krishnadasan B, Wood DE, and Flum DR. Management of pleural space infections: a population-based analysis. *J Thorac Cardiovasc Surg*. 2007;133(2):346-51.
3. Desrumaux A, Francois P, Pascal C, Cans C, Croize J, Gout JP, et al. [Epidemiology and clinical characteristics of childhood parapneumonic empyemas]. *Arch Pediatr*. 2007;14(11):1298-303.
4. Maskell NA, Davies CW, Nunn AJ, Hedley EL, Gleeson FV, Miller R, et al. U.K. Controlled trial of intrapleural streptokinase for pleural infection. *N Engl J Med*. 2005;352(9):865-74.
5. Rahman NM, Maskell NA, West A, Teoh R, Arnold A, Mackinlay C, et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. *N Engl J Med*. 2011;365(6):518-26.
6. Corcoran JP, Hallifax R, and Rahman NM. New therapeutic approaches to pleural infection. *Curr Opin Infect Dis*. 2013;26(2):196-202.
7. Tillett WS, and Sherry S. The Effect In Patients Of Streptococcal Fibrinolysin (Streptokinase) And Streptococcal Desoxyribonuclease On Fibrinous, Purulent, and Sanguinous Pleural Exudations. *J Clin Invest*. 1949;28(1):173-90.
8. Janda S, and Swiston J. Intrapleural fibrinolytic therapy for treatment of adult parapneumonic effusions and empyemas: a systematic review and meta-analysis. *Chest*. 2012;142(2):401-11.
9. Cameron R, and Davies HR. Intra-pleural fibrinolytic therapy versus conservative management in the treatment of adult parapneumonic effusions and empyema. *Cochrane Database Syst Rev*. 2008(2):CD002312.
10. Redden MD, Chin TY, and van Driel ML. Surgical versus non-surgical management for pleural empyema. *Cochrane Database Syst Rev*. 2017;3:CD010651.
11. Tucker T, and Idell S. Plasminogen-plasmin system in the pathogenesis and treatment of lung and pleural injury. *Semin Thromb Hemost*. 2013;39(4):373-81.
12. Piccolo F, Pitman N, Bhatnagar R, Popowicz N, Smith NA, Brockway B, et al. Intrapleural tissue plasminogen activator and deoxyribonuclease for pleural infection. An effective and safe alternative to surgery. *Ann Am Thorac Soc*. 2014;11(9):1419-25.
13. Komissarov AA, Mazar AP, Koenig K, Kudowska AK, and Idell S. Regulation of intrapleural fibrinolysis by urokinase-alpha-macroglobulin complexes in tetracycline-induced pleural injury in rabbits. *Am J Physiol Lung Cell Mol Physiol*. 2009;297(4):L568-L77.
14. Idell S, Jun NM, Liao H, Gazar AE, Drake W, Lane KB, et al. Single-chain urokinase in empyema induced by Pasturella multocida. *Exp Lung Res*. 2009;35(8):665-81.
15. Idell S, Allen T, Chen S, Koenig K, Mazar A, and Azghani A. Intrapleural activation, processing, efficacy, and duration of protection of single-chain urokinase in evolving tetracycline-induced pleural injury in rabbits. *Am J Physiol Lung Cell Mol Physiol.* 2007;292(1):L25-L32.

16. Idell S, Mazar A, Cines D, Kuo A, Parry G, Gawlak S, et al. Single-Chain Urokinase Alone or Complexed to Its Receptor in Tetracycline-induced Pleuritis in Rabbits. *Am J Respir Crit Care Med.* 2002;166(7):920-6.

17. Karandashova S, Florova G, Azghani AO, Komissarov AA, Koenig K, Tucker TA, et al. Intrapleural adenoviral delivery of human plasminogen activator inhibitor-1 exacerbates tetracycline-induced pleural injury in rabbits. *Am J Respir Crit Care Med.* 2013;48(1):44-52.

18. Komissarov AA, Florova G, Azghani AO, Buchanan A, Boren J, Allen T, et al. Dose dependency of outcomes of intrapleural fibrinolytic therapy in new rabbit empyema models. *Am J Physiol Lung Cell Mol Physiol.* 2016;311(2):L389-99.

19. Idell S, and Rahman NM. Intrapleural Fibrinolytic Therapy for Empyema and Pleural Loculation: Knowns and Unknowns. *Ann Am Thorac Soc.* 2018;15(5):515-7.

20. Komissarov AA, Rahman N, Lee YCG, Florova G, Shetty S, Idell R, et al. Fibrin turnover and pleural organization: bench to bedside. *Am J Physiol Lung Cell Mol Physiol.* 2018;314(5):L757-L68.

21. Florova G, Azghani A, Karandashova S, Schaefer C, Koenig K, Stewart-Evans K, et al. Targeting of plasminogen activator inhibitor 1 improves fibrinolytic therapy for tetracycline-induced pleural injury in rabbits. *Am Respir Cell Mol Biol.* 2015;52(4):429-37.

22. Idell S, Florova G, Shetty S, Tucker T, Idell R, Koenig K, et al. Precision-guided, Personalized Intrapleural Fibrinolytic Therapy for Empyema and Complicated Parapneumonic Pleural Effusions: The Case for the Fibrinolytic Potential. *Clin Pulm Med.* 2017;24(4):163-9.

23. Tillett WS, Sherry S, and Read CT. The use of streptokinase-streptodornase in the treatment of postneumonic empyema. *J Thorac Surg.* 1951;21(3):275-97.

24. Lee YC, Idell S, and Stathopoulos GT. Translational Research in Pleural Infection and Beyond. *Chest.* 2016.

25. Popowicz N, Idell S, and Lee YCG. Pathogenesis of pleural infection: A complex warfare. *Respirology.* 2018;23(1):8-9.

26. Philip-Joet F, Alessi MC, Philip-Joet C, Aillaud M, Barriere JR, Arnaud A, et al. Fibrinolytic and inflammatory processes in pleural effusions. *Eur Respir J.* 1995;8(8):1352-6.

27. Chiu CY, Wong KS, Huang JL, Tasi MH, Lin TY, and Hsieh SY. Proinflammatory cytokines, fibrinolytic system enzymes, and biochemical indices in children with infectious para-pneumonic effusions. *Pediatr Infect Dis J.* 2008;27(8):699-703.

28. Aleman C, Porcel JM, Alegre J, Ruiz E, Bielsa S, Andreu J, et al. Intrapleural Fibrinolysis with Urokinase Versus Alteplase in Complicated Parapneumonic Pleural Effusions and Empyemas: A Prospective Randomized Study. *Lung.* 2015;193(6):993-1000.

29. Majid A, Kheir F, Folch A, Fernandez-Bussy S, Chatterji S, Maskey A, et al. Concurrent Intrapleural Instillation of Tissue Plasminogen Activator and DNase for Pleural Infection. A Single-Center Experience. *Ann Am Thorac Soc.* 2016;13(9):1512-8.

30. Popowicz N, Bintcliffe O, De Fonseka O, De Fonseka D, Blyth KG, Smith NA, Piccolo F, et al. Dose De-escalation of Intrapleural Tissue Plasminogen Activator Therapy for Pleural Infection. The Alteplase Dose Assessment for Pleural Infection Therapy Project. *Ann Am Thorac Soc.* 2017;14(6):929-36.

31. Florova G, Aghzani AO, Karandashova S, Schaefer C, Yarovoi SV, Declerck PJ, et al. Targeting plasminogen activator inhibitor-1 in tetracycline-induced pleural injury in rabbits. *Am J Physiol Lung Cell Mol Physiol.* 2018;314(1):L54-L68.

32. Komissarov AA, Florova G, Aghzani AO, Buchanan A, Bradley WM, Schaefer C, et al. The time course of resolution of adhesions during fibrinolytic therapy in tetracycline-induced pleural injury in rabbits. *Am J Physiol Lung Cell Mol Physiol.* 2015:ajplung.
33. Idell S. Update on the Use of Fibrinolysins in Pleural Disease. *Clinical Pulmonary Medicine*. 2005;12(3):184-90.
34. Gervais DA, Levis DA, Hahn PF, Uppot RN, Arellano RS, and Mueller PR. Adjunctive intrapleural tissue plasminogen activator administered via chest tubes placed with imaging guidance: effectiveness and risk for hemorrhage. *Radiology*. 2008;246(3):956-63.
35. Anevavis S, Archontogeorgis K, Tzouvelekis A, Kouliatis G, Pozova S, Bougioukas I, et al. Intrapleural r-tPA in association with low-molecular heparin may cause massive hemothorax resulting in hypovolemia. *Respiration*. 2011;81(6):513-6.
36. Editors. Blood Transfusion *National Clinical Guideline Centre (UK)*. London; 2015.
37. Guth MC, Kaufner L, Kleber C, and von Heymann C. [Therapy of trauma-induced coagulopathy - what is the evidence?]. *Anasthesiol Intensivmed Notfallmed Schmerzther*. 2012;47(9):528-39; quiz 40.
38. Schlimp CJ, and Schochl H. The role of fibrinogen in trauma-induced coagulopathy. *Hamostaseologie*. 2014;34(1):29-39.
39. Idell S, Girard W, Koenig KB, McLarty J, and Fair DS. Abnormalities of pathways of fibrin turnover in the human pleural space. *American Review of Respiratory Disease*. 1991;144(1):187-94.
40. Chung CL, Chen CH, Sheu JR, Chen YC, and Chang SC. Proinflammatory cytokines, transforming growth factor-beta1, and fibrinolytic enzymes in loculated and free-flowing pleural exudates. *Chest*. 2005;128(2):690-7.
41. Idell S, Azghani A, Chen S, Koenig K, Mazar A, Kodandapani L, et al. Intrapleural low-molecular-weight urokinase or tissue plasminogen activator versus single-chain urokinase in tetracycline-induced pleural loculation in rabbits. *Exp Lung Res*. 2007;33(8):419-40.
Figure 1. Protocol Flow Chart

Standard of care procedures required, which may include:
- Chest X-ray
- Chest CT scan, ultrasound
- Blood test
- Tube inserted into chest to drain fluid
- Pleural fluid samples collected

If fluid is fully drained after 3 hours

Normal standard of care

If fluid remains after 3 hours

Consent to study

No

Consent to optional study (storing tissue samples for future research)

Yes

Screening
- Medical history, physical exam, vital signs
- Blood and pleural fluid samples
- Chest X-ray, CT scan, ultrasound (if not performed earlier)
- Urine and blood pregnancy test (if applicable)

If not eligible for the study

Normal standard of care

If eligible for the study

Prior to treatment
- Medical history, physical exam, vital signs
- Blood and pleural fluid samples (3 hours prior)

Treatment
- LTI-01 is injected directly into the lung cavity through the chest tube
- Chest tube will be clamped for 3 hours

After treatment
- Blood and pleural fluid samples at 3 and 23 hours
- Vital signs at 3, 6, 12 and 18 hours

Day 1
1st Dose

Day 2
2nd Dose

Day 3
3rd Dose

Day 4 or End of Treatment
(Approximately 23 hours after last dose)
- Physical exam, vital signs
- Blood and pleural fluid samples
- Chest X-ray, CT scan, ultrasound

At Discharge or Day 28
- Final blood sample

About 3 and 12 months after treatment, information on health status will be collected
Figure 2. Successful delivery of LTI-01 to the pleural space (A) coincided with an increase in plasminogen activating (PA) (B), fibrinolytic (C) activities and level of fibrin degradation product (D-dimers) (D) in pleural fluid at 3h post treatment and did not affect levels of uPA antigen (E) or D-dimers in plasma (F). LTI-01 was delivered daily at doses of 50 000 (pink symbols; n=3), 100 000 (blue symbols; n=3), 200 000 (orange symbols; n=3), 400 000 (purple symbols; n=3) and 800 000 (green symbols; n=2) IU per injection. Samples of pleural fluid (Day 1 pre-treatment n= 12, Day1 post-treatment n= 14, Day 2 pre-treatment n= 9, Day 2 post-treatment n= 13, Day 3 pre-treatment n= 2, Day 3 post-treatment n= 8 and Day 4 n= 4) and plasma (Day1 and pre-Day3 pre-treatment n=14 each, Day 3 post-treatment n=5 and Day 4 n=5) were collected daily (1-4 days) just prior to each LTI-01 injection (pre) and 3 h after (post) treatment as described in the Materials and Methods section. Levels of urokinase antigen were determined in pleural fluid (A) and plasma (E) using ELISA analyses (R&D Systems, MN). Plasminogen activating activity in pleural fluid (B) was determined by measuring the rates of activation of exogenously added human Glu-Pasminogen (200 nM) and fluorogenic plasmin substrate (200 µM) SN-5 (HTI, VT) as previously described (21). The fibrinolytic activity in pleural fluid (C) was measured by FITC-fibrin assay, as described elsewhere (21). D-dimers were determined in pleural fluid (D) and plasma (F) using ELISA (Abcam, MA). The plasma samples collected from the patient diagnosed with metastatic squamous cell carcinoma are excluded from the analysis. Each point represents an average of at least two independent measurements. Data are presented as dot plots with horizontal lines indicating the medians and whiskers representing interquartile range; * P<0.05; ** P<0.001; *** P<0.0001; ns P≥0.05 using the Wilcoxon matched-pairs signed rank test (assessed at the 5% level of significance). Dashed line indicates the lowest limit of detection (LOD) of the method.
Figure 3. Inhibition of plasminogen activating (PA), fibrinolytic activities prior to and during IPFT with LTI-01 and correlation of the FP with reduction of pleural opacification by CXR.

Levels of plasminogen activator inhibitor 1 (PAI-1) activity (A), antigen (B) and A2M/uPA complexes (C) were determined. LTI-01 was delivered daily with doses 50 000 (pink symbols; n=3; 12 samples), 100 000 (blue symbols; n=3; 9 samples), 200 000 (orange symbols; n=3; 4 samples), 400 000 (purple symbols; n=3; 10 samples) and 800 000 (green symbols; n=2; 6 samples) IU per injection. Samples of pleural fluid (Day 1 pre-treatment n=12, Day 1 post-treatment n=14, Day 2 pre-treatment n=9, Day 2 post-treatment n=13, Day 3 pre-treatment n=2, Day 3 post-treatment n=8 and Day 4 n=4) were collected daily (1-4 days) prior to each LTI-01 injection (pre) and 3 h after (past) treatment as described in the Materials and Methods section. Levels of PAI-1 antigen and PAI-1 activity were determined in pleural fluid (A) using ELISA (Molecular Innovations, MI). Levels of bioactive alpha 2-macroglobulin/uPA (A2M/uPA) (C) complexes were determined as described elsewhere(13). Each point represents an average of at least two independent measurements. Data are presented as dot plots with horizontal lines indicating the medians and whiskers representing interquartile range; * P<0.05; ** P<0.001; *** P<0.0001; ns P≥0.05 using the Wilcoxon matched-pairs signed rank test (assessed at the 5% level of significance). Correlation (D) between fibrinolytic potential (FP) and clinical outcome after IPFT with LTI-01 (n=8; r=-0.79; p<0.05 by Spearman rank correlation). FP was determined in samples of PF collected prior to the IPFT as previously described(21, 22). The values of % of changes in relative pleural density on CXR prior to (E) and after (F)
IPFT with LTI-01 were calculated as previously described. The solid line represents the best fit of a linear equation to the data; with the % of relative changes in X-ray pleural density area (Table 3).

### Table 1: Baseline Demographics for all Subjects (ITT Population)

| Parameter | Statistics | LTI-01 50,000 IU (N=3) | LTI-01 100,000 IU (N=3) | LTI-01 200,000 IU (N=3) | LTI-01 400,000 IU (N=3) | LTI-01 800,000 IU (N=2) | All LTI-01 (N=14) |
|-----------|------------|------------------------|-------------------------|------------------------|------------------------|------------------------|------------------|
| Sex       |            |                        |                         |                        |                        |                        |                  |
| Female    | n (%)      | 1 (33.3%)              | -                       | -                      | 1 (33.3%)              | 1 (50.0%)              | 3 (21.4%)        |
| Male      | n (%)      | 2 (66.7%)              | 2 (66.7%)               | 3 (66.7%)              | 2 (50.0%)              | 11 (78.6%)             |                  |
| Age (years) |            | Mean 59.3              | 52.3                    | 69.0                   | 75.7                   | 70.0                   | 64.9             |
|           |            | Min 52                 | 42                      | 57                     | 72                     | 51                     | 42               |
|           |            | Max 71                 | 61                      | 78                     | 78                     | 89                     | 89               |
| BMI (kg/m²) |            | Mean 24.95             | 25.27                   | 19.07                  | 26.50                  | 24.15                  | 23.68            |
|           |            | Min 22.4               | 17.4                    | 15.9                   | 25.1                   | 24.0                   | 15.9             |
|           |            | Max 27.5               | 33.1                    | 24.7                   | 27.9                   | 24.3                   | 33.1             |
| Race      |            |                        |                         |                        |                        |                        |                  |
| White     | n (%)      | 3 (100.0%)             | 2 (66.7%)               | 2 (66.7%)              | 3 (100.0%)             | 1 (50.0%)              | 11 (78.6%)       |
| Other*    | n (%)      | -                      | 1 (33.3%)               | 1 (33.3%)              | -                      | 1 (50.0%)              | 3 (21.4%)        |

* Three patients were of Maori, Tongan or Philippine descent.
## Table 2: Treatment-Emergent Adverse Events by Treatment Group

|                              | LTI-01 50,000 IU (N=3) | LTI-01 100,000 IU (N=3) | LTI-01 200,000 IU (N=3) | LTI-01 400,000 IU (N=3) | LTI-01 800,000 IU (N=2) | All LTI-01 (N=14) |
|------------------------------|------------------------|-------------------------|------------------------|------------------------|------------------------|------------------|
| Vascular disorders           | 1 (33.3%)              | 1 (33.3%)               | 2 (66.7%)              | 0                      | 0                      | 4 (28.6%)        |
| Hypotension                  | 1 (33.3%)              | 0                       | 2 (66.7%)              | 0                      | 0                      | 3 (21.4%)        |
| Phlebitis                    | 0                      | 1 (33.3%)               | 0                      | 0                      | 0                      | 1 (7.1%)         |
| Investigations               | 1 (33.3%)              | 1 (33.3%)               | 1 (33.3%)              | 0                      | 0                      | 3 (21.4%)        |
| Body temperature increased   | 1 (33.3%)              | 1 (33.3%)               | 0                      | 0                      | 0                      | 2 (14.3%)        |
| Hemoglobin decreased         | 0                      | 0                       | 1 (33.3%)              | 0                      | 0                      | 1 (7.1%)         |
| PT prolonged                 | 0                      | 1 (33.3%)               | 0                      | 0                      | 0                      | 1 (7.1%)         |
| WBC count increased          | 0                      | 1 (33.3%)               | 0                      | 0                      | 0                      | 1 (7.1%)         |
| Respiratory, thoracic and mediastinal disorders | 2 (66.7%) | 1 (33.3%) | 0 | 0 | 0 | 3 (21.4%) |
| Pleuritic pain               | 1 (33.3%)              | 1 (33.3%)               | 0                      | 0                      | 0                      | 2 (14.3%)        |
| Pleural effusion             | 1 (33.3%)              | 0                       | 0                      | 0                      | 0                      | 1 (7.1%)         |
| Infections and infestations  | 0                      | 1 (33.3%)               | 0                      | 1 (33.3%)              | 0                      | 2 (14.3%)        |
| Lung abscess                 | 0                      | 0                       | 0                      | 1 (33.3%)              | 0                      | 1 (7.1%)         |
| Respiratory syncytial virus infection | 0 | 1 (33.3%) | 0 | 0 | 0 | 1 (7.1%) |
| Injury, poisoning and procedural complications | 1 (33.3%) | 0 | 1 (33.3%) | 0 | 0 | 2 (14.3%) |
| Post procedural hematoma     | 0                      | 0                       | 1 (33.3%)              | 0                      | 0                      | 1 (7.1%)         |
| Post procedural persistent drain fluid | 1 (33.3%) | 0 | 0 | 0 | 0 | 1 (7.1%) |

**Legend:** Table restricted to System Organ Class (SOC)s for which >1 subject reported a TEAE. Numbers of events and percentages (in brackets) for each category of TEAE are presented.
| Subject ID | Dose of LTI-01 (IU) | Relative Change in % Pleural Density Area (%) By CXR* | Relative Change in Pleural Density volume (%) by CT* |
|------------|---------------------|-------------------------------------------------|-------------------------------------------------|
| 102-1001   | 50,000              | -85%                                            | -69%                                            |
| 202-1001   | 50,000              | 4%                                              | 83%                                             |
| 202-1002   | 50,000              | -42%                                            | NA                                              |
| 102-1002   | 100,000             | -15%                                            | -36%                                            |
| 103-1001   | 100,000             | -83%                                            | NA**                                            |
| 202-1003   | 100,000             | -55%                                            | NA                                              |
| 102-1003   | 200,000             | -71%                                            | -72%                                            |
| 102-1004   | 200,000             | -37%                                            | -46%                                            |
| 202-1004   | 200,000             | NA                                              | -62%                                            |
| 102-1005   | 400,000             | NA                                              | -45%                                            |
| 202-1005   | 400,000             | -38%                                            | -38%                                            |
| 102-1006   | 400,000             | NA                                              | -31%                                            |
| 102-1007   | 800,000             | -36%                                            | -58%                                            |
| 103-1002   | 800,000             | -85%                                            | NA                                              |

* Relative change in pleural opacification: Change in pleural opacification recorded as the basal opacity-the post-treatment opacification divided by the basal opacification, as described in the Materials and Methods section. ** NA = not available.
Legend. CT rendition from case 102-1007 (800,000 IU dosing) illustrating color mapping of the extent of pleural opacification as indicated in yellow in the lateral projection shown. The underlying lung is indicated in orange. The pre-treatment (day-1) CT projection is illustrated in the left panel and the post-treatment CT at day 4 is shown on the right. Calculation of the relative decrease in pleural opacification in the volume of the pleural opacification after treatment; -58% here, was done as previously described(5). The green icon shows the orientation of each of the images with the arrow indicating the facial orientation. The red text indicates that the patient was imaged in the supine position.